standard care – Page 14 – Communicable Diseases Research

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

코로나19 폐렴으로 입원한 환자의 토실리주맙

Randomized Controlled Trial

Published on 2021-01-072022-09-11
Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 임상, 진단,

Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study

코로나바이러스 질병-2019에 대한 치료용 혈장 교환은 사이토카인 방출 증후군을 유발했습니다. 후향적 성향 일치 대조 연구

Research Article

Published on 2021-01-072022-08-13
Journal: PLoS ONE [Category] Biochemistry, COVID-19, MERS,

[키워드] 1:1 95% CI Analysis analyzed assigned both groups Cohort Control controls coronavirus coronavirus disease coronavirus disease-2019 COVID-19 Critical CRS cytokine cytokine release Cytokine release syndrome Cytokines discharge disease severity duration of hospitalization evaluate Forced groups hospital hospitalized patient in both group log rank male males median age moderate Mortality non-randomized objective outcome pathogenic pathophysiology Patient plasma plasma exchange polymerase chain reaction Polymerase chain reaction testing Primary outcome progression PSM reduced Result retrospective secondary Secondary outcomes selected severity significantly standard care Standard of care supportive care survival Symptom syndrome the patient Therapeutic plasma exchange TPE treated Treatment triggered Viral viral clearance was done was used with COVID-19
[DOI] 10.1371/journal.pone.0244853 PMC 바로가기 [Article Type] Research Article

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial

COVID-19 폐렴으로 입원한 환자의 임상 악화에 대한 Tocilizumab 대 표준 치료의 효과: 무작위 임상 시험

Randomized Controlled Trial

Published on 2021-01-012022-09-12
Journal: JAMA Internal Medicine [Category] 임상, 진단,

[키워드] 95% CI age benefit blinded C-reactive protein causes clinical Clinical Center control arm control group coronavirus disease COVID-19 criteria death defined died Disease progression Effect elevated EudraCT evaluate evaluate the effect experimental arm experimental group Fever fraction groups hospital Hospitalized inflammatory phenotype intensive care Intention-to-treat analyses interim analysis interquartile range intravenous tocilizumab Intubated Invasive mechanical ventilation Italy less majority male median Nasopharyngeal swab NCT04346355 Open-label outcome oxygen pandemic Patient patients hospitalized patients with COVID-19 placebo-controlled Pneumonia polymerase chain Prospective protocol radiologic imaging randomization Randomized randomized clinical trial randomized patient receive Retrospective study safety profile second dose shown Stage Standard standard care standard care group Standard of care Standard therapy supportive care the disease therapy Tocilizumab tocilizumab administration Trial Two patient with COVID-19 worsening
[DOI] 10.1001/jamainternmed.2020.6615 PMC 바로가기 [Article Type] Randomized Controlled Trial

Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study

로피나비르/리토나비르 대 히드록시클로로퀸 간의 경증 내지 중등도 COVID-19 사례에 대한 항바이러스 효과 비교: 전국적인 성향 점수 일치 코호트 연구

Comparative Study

Published on 2021-01-012022-09-11
Journal: International Journal of Infectious Diseases [Category] SARS, 치료제,

[키워드] age Analysis Antiviral effect benefit case-control study cohort study conducted control group control groups controls COVID-19 COVID-19 case determine HCQ Health Insurance Hydroxychloroquine insurance IQR Lopinavir Lopinavir/ritonavir malignancy median Mild-to-moderate Multivariate analysis National Health Insurance not significantly different old age Patient patients with COVID-19 Pneumonia prolonged viral shedding propensity score matching PSM retrospective risk factor Ritonavir SARS-CoV-2 service standard care statistically significant steroid steroid use three groups treatment groups Viral viral clearance viral shedding
[DOI] 10.1016/j.ijid.2020.10.062 PMC 바로가기 [Article Type] Comparative Study

Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis

COVID-19 치료를 위한 약리학적 중재의 비교 효능 및 안전성: 체계적인 검토 및 네트워크 메타 분석

Meta-Analysis

Published on 2020-12-302022-08-13
Journal: PLoS Medicine [Category] Biology and Life Sciences, MERS, meta-analysis, 임상,

[키워드] 1.26 95% CI 95% confidence interval Admission aggravation Alpha Anakinra analyses Analysis anti-inflammatory agent anti-inflammatory agents Asia assessment associations Azithromycin benefit Cardiac complications cardiac safety risk cardiac safety risks cardiac-impaired population cardiac-impaired populations carried categories category Causality certainty clinical clinical benefit clinical benefits Clinical outcome clinical settings clinical trial ClinicalTrials clinician Cochrane Library collected Combination Comparative controlled trials convalescent plasma coronavirus disease Coronavirus disease 2019 Corticosteroid Corticosteroids Course COVID-19 COVID-19 disease COVID-19 disease course COVID-19 treatments CRD42020186527 Critically ill Critically ill patient critically ill patients daclatasvir dataset determine development disease course drug effective Efficacy and safety eligibility criteria eligible Europe evaluate Evidence evidence of fatal cardiac complication fatal cardiac complications Google Scholar help heterogeneous High-dose Hospitalization hospitalized COVID-19 patients Hydroxychloroquine ICU Immunoglobulin information intensive care intensive care unit interferon interferon-alpha Intravenous immunoglobulin investigated itolizumab Ivermectin IVIG Level management mechanical ventilation medRxiv Meta-analysis Middle East mild patients moderate moderate to severe moderate/high evidence certainty Mortality mortality rate mortality rates Network meta-analysis NMA non-ICU non-ICU setting noncardiac serious adverse events North America Numerous observational studies observational study Odds ratio outcome Patient patients hospitalized pharmacological agent pharmacological intervention pharmacological interventions pharmacological management plasma Policy populations Potential treatment potential treatments progression PROSPERO provide QT prolongation QT prolongation incidence Randomized controlled trial Randomized controlled trials randomized trial randomized trials RCT RCTs recommendations reduce reduce COVID-19 aggravation reduce mortality rate reduced reflected registry Remdesivir Research researcher Result risk risk of bia RoB RoB2 ROBINS-I framework searched self-limiting disease Serious Adverse Event Serious Adverse Events severe COVID-19 patient severe disease severe pneumonia shown significantly sofosbuvir sofosbuvir plus daclatasvir South America SSRN standard care Study protocol supported systematic review systematic synthesis Tocilizumab translated Treatment treatment regimen viral clearance rate vulnerable population WHO WHO International Clinical Trials Registry Platform
[DOI] 10.1371/journal.pmed.1003501 PMC 바로가기 [Article Type] Meta-Analysis

Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial

입원한 중증 COVID-19 환자를 위한 치료제로서의 정맥내 메틸프레드니솔론 펄스: 무작위 대조 임상 시험의 결과

Randomized Controlled Trial

Published on 2020-12-242022-08-13
Journal: The European Respiratory Journal [Category] 임상,

[키워드] 1:1 95% CI administration Analysis attending physician Block randomisation Clinical improvement clinical trial conducted Controlled clinical trial Corticosteroid Corticosteroids COVID-19 COVID-19 patient COVID-19 patients death demonstrated eligible patient hazard ratio hospitalised hospitalised patient Immunosuppressive treatment Inflammation Inflammatory marker inflammatory markers initiation of treatment intention-to-treat Intravenous injection Iran ITT log-rank test Methylprednisolone methylprednisolone group mortality rate oxygen oxygen saturation Patient pulmonary involvement pulse randomisation randomised controlled Randomly receive reduce respiratory Respiratory system Result safety analysis severe adverse event severe adverse events severe COVID-19 severe COVID-19 patient significantly increased significantly lower single-blind standard care standard care group suggested survival survival time therapeutic therapeutic agent Treatment Two patient two patients was done were excluded
[DOI] 10.1183/13993003.02808-2020 PMC 바로가기 [Article Type] Randomized Controlled Trial

A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment

코로나19 치료에서 클로로퀸과 하이드록시클로로퀸 단독요법 또는 아지스로마이신과의 병용요법에 대한 체계적인 검토 및 메타분석

Meta-Analysis

Published on 2020-12-172022-09-10
Journal: Scientific Reports [Category] SARS, 임상, 치료법, 치료제,

[키워드] 95% CI 95% confidence interval Analysis article Azithromycin calculated can not carried Chain Reaction Chloroquine CIs Combination coronavirus COVID-19 cure rate database Diseases drug side effects Effect Effectiveness examined exposure to Future good quality group HCQ Hospital stay Hydroxychloroquine IMPROVE Infectious diseases investigated mechanical ventilation Meta-analysis meta-regression monotherapy Mortality mortality rate not differ not different observational studies observational study Patient PCR polymerase chain polymerase chain reaction radiological improvement radiological progression random-effects model randomized control trial RCT relative risks reported risk RRs scarcity side Side effects significantly significantly higher standard care statistically systematic review treating COVID-19 Treatment Viral viral infection was performed worsening
[DOI] 10.1038/s41598-020-77748-x PMC 바로가기 [Article Type] Meta-Analysis

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

코로나19로 입원한 환자에서 토실리주맙의 효능

Randomized Controlled Trial

Published on 2020-12-102022-09-12
Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 임상, 진단,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome analyses assigned baseline benefit blockade body temperature comparison confidence interval coronavirus coronavirus disease death disease double-blind effective Efficacy enrolled Fever greater hazard ratio Hispanic hospitalized patient Hyperinflammatory Infection interleukin-6 receptor intubation Latino maintain mechanical ventilation median age median time men outcome oxygen saturation Patient performed Placebo placebo-controlled trial Primary outcome pulmonary infiltrates Randomized Randomly receive receiving SARS-CoV-2 serious infection single dose standard care supplemental oxygen the patient the placebo group time-to-event analysis Tocilizumab women worsening
[DOI] 10.1056/NEJMoa2028836 PMC 바로가기 [Article Type] Randomized Controlled Trial

Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study

Research

Published on 2020-12-102022-11-01
Journal: Critical Care [Category] COVID-19, MERS,

[키워드] aligned Anakinra Analysis analyzed Aspartate aminotransferase Bilirubin both groups Characteristics circulating cytokine clinical clinical feature Clinical outcome clinical outcomes clinical parameter Clinical sign Concentration control group Coronavirus disease 2019 Corticosteroids COVID-19 COVID-19 patient COVID-19 patients creatinine criteria Critical care Critically ill Cytokines decrease develop Diseases Effect effective elevated ferritin Fever groups hyperinflammation Hyperinflammatory hyperinflammatory state ICU ICU admission Immunity inflammatory parameter interleukin-1 receptor antagonist protein investigated mechanical ventilation mechanically ventilated median outcome parameters Patient plasma procalcitonin prospective cohort study Randomized controlled trial receive receptor reducing Result SARS-CoV-2 sensitivity analysis significantly higher standard care subset temperature treated Treatment treatment group was performed White blood cell
[DOI] 10.1186/s13054-020-03364-w PMC 바로가기 [Article Type] Research

Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: A retrospective study from Burkina Faso and simulated case analysis

사하라 사막 이남 아프리카의 COVID-19 사례 중 임상 관리 및 사망률: 부르키나 파소의 후향적 연구 및 모의 사례 분석

Article

Published on 2020-12-012022-09-10
Journal: International Journal of Infectious Diseases [Category] MERS, SARS, 치료제,

[키워드] 95% CI adjusted African age aggregate Americas Analysis analyzed Asia Burkina Faso Care Caregivers case fatality rates clinical Clinical characteristics clinical information Clinical management of SARS-CoV-2 infection: convalescent plasma Community Comorbidities component conducted convalescent plasma country COVID-19 COVID-19 case COVID-19 cases COVID-19 mortality Critical curative death Deceased Delayed demographic demographic and clinical characteristics demographic data diabete diabetes disparity distribution distributions effect sizes Effectiveness epidemiological Europe evaluate fatality Health systems strengthening healthcare providers Highlights Hospitalized hypertension Impact information Intervention Investment Logistic regression analysis maintenance majority male management Mortality over oxygen Oxygen therapy Patient patients receiving oxygen Population prevalent receiving reduce reduced regression analysis reported respiratory respiratory illnesses Result Retrospective study risk risk factor SARS-COV-2 infection seeking Sex significantly higher significantly lower SSA standard care sub-Saharan Africa suggested survival the epidemic therapeutic therapy treating COVID-19 Treatment underlying condition underlying conditions West
[DOI] 10.1016/j.ijid.2020.09.1432 PMC 바로가기 [Article Type] Article